Xvivo Perfusion AB

Xvivo Perfusion AB maintains a strong liquidity position with a current ratio of 5.77 and cash and equivalents of 291.79 million SEK, indicating the company has sufficient short-term assets to cover its liabilities. The company's price-to-book ratio of 4.13 suggests that the market values the company at a premium to its book value, while the price-to-tangible-book ratio of 4.13 is identical, indicating no intangible assets are being capitalized. Profitability metrics show a return on equity of 1.19% and a return on assets of 1.06%, which are relatively low compared to industry benchmarks. The company's operating income of 88.38 million SEK and net income of 25.16 million SEK indicate modest profitability, with a gross profit of 599.49 million SEK showing strong cost control in production. The company's revenue is primarily concentrated in the medical equipment segment, with no disclosed geographic breakdown. This concentration may expose the company to risks associated with changes in demand for heart-lung machines and disposable products in the healthcare sector. Looking ahead, the company is projected to maintain a stable revenue trajectory, with no significant growth or decline expected in the next fiscal year. The free cash flow of -157.54 million SEK indicates that the company is currently investing heavily in capital expenditures, which may impact short-term liquidity. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.06 suggests a conservative capital structure with minimal long-term debt exposure. Recent events include analyst estimates with a mean price target of 341.00 SEK and a median price target of 340.00 SEK, indicating a generally positive outlook from analysts. The mean recommendation of 1.60 suggests a strong buy rating, with 2 strong-buy and 3 buy recommendations reported.